BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
土曜日, 9 26

Mineralys Therapeutics Inc

MLYSNASDAQ
Trade with Public
Trade with Public
$25.86
-0.73-2.75%
近くで: Sep 25, 5:00 PM EST
$25.86
N/A
時間外: 4:00 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Mineralys Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Mineralys Therapeutics (MLYS).

Price Target Range — 8 Quarters

Analyst Consensus — 8 Analysts

7Buy
1Hold
Consensus RatingBuy# Analysts8Avg. Consensus PT$49Upside to Avg. PT+88.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →
DateFirmAnalystActionRating ChangePrice Target
Apr 27, 2026TD CowenTara BancroftInitiateBuy—
Mar 13, 2026B of A SecuritiesGreg HarrisonPT RaiseBuy$46→$51
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
TD Cowen Initiates Coverage On Mineralys Therapeutics with Buy Rating

TD Cowen analyst Tara Bancroft initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Mineralys Therapeutics, Raises Price Target to $51

B of A Securities analyst Greg Harrison maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $46 to $51.
Benzinga Newsdesk

PRO
Stifel Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52

Stifel analyst Annabel Samimy maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $45 to $52.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $56

HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $52 to $56.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Mineralys Therapeutics, Raises Price Target to $55

Wells Fargo analyst Mohit Bansal maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Overweight and raises the price target from $50 to $55.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52

HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $42 to $52.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved